Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-315

"Unlike Kymriah, Novartis's cancer cell therapy, Remestemcel-L does not have to be tailored for each patient. Once the deal is closed, Novartis said it is planning to help Mesoblast work on quality attributes of the therapy so it meets U.S. Food and Drug Administration requirements necessary for late-stage trial beyond COVID-19."

I bet they do! as I said, you need all the help you can get to actually manufacture your product at scale and that's why Novartis has stolen Rem-L (Osiris dump) for the paltry $25m which only covers product costs manufactured to date for mostly the big ARDs result.

I have asked this question now multiple times....only abuse followed, so can you do any better

WHEN will the magic 3D bioreactor and serum free media be actually making products now? GIVEN your own CEO has admitted in last annual report you will need to start again in pre-clinical?

No one has yet refuted this FACT